Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) shares traded down 8.1% during trading on Tuesday . The stock traded as low as $2.75 and last traded at $2.85. 2,377 shares traded hands during trading, a decline of 43% from the average session volume of 4,197 shares. The stock had previously closed at $3.10.
Cyclerion Therapeutics Trading Up 5.2 %
The business’s 50-day moving average price is $3.01 and its 200-day moving average price is $2.93.
Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.53) EPS for the quarter.
Institutional Investors Weigh In On Cyclerion Therapeutics
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Recommended Stories
- Five stocks we like better than Cyclerion Therapeutics
- Pros And Cons Of Monthly Dividend Stocks
- 3 Leveraged ETFs to Multiply Returns
- Technology Stocks Explained: Here’s What to Know About Tech
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.